Most Types News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Дипломатический конфликт между Литвой и Китаем из-за Тайваня может сказаться на том, как страны ЕС — от государств Балтии до Венгрии и Румынии — будут взаимодействовать с Пекином.

Приближается день торжественных линеек. 1 сентября школы Сургутского района примут свыше 17 с половиной тысяч учащихся, что на 2 сотни больше, чем в прошлом году. -Новости Сургута

В заведении под сладким названием «Мед» обнаружили кучу шариков и баллонов [фото, видео]

ABBVie announced today that the European Commission has approved VENCLYXTO ® in combination with a hypomethylating agent, azacitidine or decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. 1 The approval is valid in all 27 member states of the EU, as well as Iceland Liechtenstein and Norway . “VENCLYXTO has proven incremental … – ABBVie (NYSE: ABBV) announced today that the European Commission (EC) has approved VENCLYXTO ® (venetoclax) in combination with a hypomethylating agent, azacitidine or d...

April 23, 2021 at 08:49 AM EDT AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy AbbVie (NYSE: ABBV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VENCLYXTO® (venetoclax) in combination with hypomethylating agents for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemoth...